Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins and Dani Blum

in

Drugs (Pharmaceuticals), Eli Lilly and Company, Food and Drug Administration, GLP-1 RAs (Drug), Hims & Hers Health Inc, Jorgensen, Lars Fruergaard, Makary, Marty, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Shortages, Telemedicine
←Shein and Temu Will be Hit by Trump’s China Tariffs. Americans Are Worried.
The Concert Cold War in a Quiet Enclave→

More posts

  • Bessent compares tech outages to vaccines

  • West Coast bracing for more coastal flooding as Thanksgiving travel week begins

  • Yoro sees red as Ngumoha shines – Liverpool v Man Utd player ratings

  • Billy Ray Cyrus’ Ex-Wife Firerose Resurfaces Past Abuse Claims Day After Miley’s Wedding

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube